The results put AstraZeneca into direct competition with Eli Lilly in the race for a convenient oral GLP-1 therapy, a market widely seen as the next major growth frontier in pharmaceuticals. Elecoglipron's 10.5% weight reduction at 26 weeks is broadly competitive with Lilly's orforglipron, which produces reductions of 8.6% to 12.6% across dosage levels over the same period. The absence of a weight-loss plateau, with results continuing to improve at 36 weeks, is a meaningful differentiator that could attract investor attention and physician interest alike. Progress into phase III keeps AstraZeneca's cardiometabolic pipeline on a credible commercial trajectory.
-
AstraZeneca's oral obesity drug elecoglipron cut body weight by 10.5% at 26 weeks vs 0.6% for placebo in a phase II trial, clearing both primary endpoints and advancing to phase III.
Summary:
- Adults with obesity or overweight and at least one comorbidity receiving elecoglipron 75mg achieved average body weight reduction of 10.5% at 26 weeks versus 0.6% with placebo
- The trial met both dual primary endpoints, including the proportion of participants achieving at least 5% weight loss, with up to 88.8% clearing that threshold on elecoglipron
- Weight loss did not plateau, reaching 11.8% at 36 weeks on the 75mg dose versus 0.3% with placebo
- AstraZeneca is advancing elecoglipron into a phase III programme as part of its cardiometabolic and kidney portfolio
- For comparison, Eli Lilly's oral GLP-1 therapy orforglipron, marketed as Foundayo for weight management, produces average body weight reductions of 8.6% to 12.6% over 26 weeks depending on dose
AstraZeneca has reported strong phase II results for elecoglipron, its oral small molecule GLP-1 receptor agonist, with the drug delivering a 10.5% average reduction in body weight after 26 weeks in adults with obesity or overweight, compared with just 0.6% in the placebo group.
The trial cleared both dual primary endpoints. In addition to the mean weight reduction, up to 88.8% of participants on the 75mg dose achieved at least 5% body weight loss at 26 weeks, a clinically meaningful threshold that regulators and physicians use to assess the real-world utility of obesity therapies.
Crucially, the weight loss did not plateau within the trial window. Participants on elecoglipron continued to shed weight through to the final 36-week assessment, reaching an average reduction of 11.8% on the 75mg dose, while the placebo group registered just 0.3% over the same period. That trajectory matters commercially: sustained loss without a plateau suggests elecoglipron could deliver greater benefit over longer treatment durations, which are typical in obesity management.
The results are sufficient to carry elecoglipron into a phase III programme, a significant milestone that validates AstraZeneca's strategy of building out its cardiometabolic and kidney portfolio beyond its established oncology and respiratory franchises.
The development puts AstraZeneca in direct competition with Eli Lilly, whose oral GLP-1 therapy orforglipron was recently approved and is now marketed as Foundayo for weight management. Lilly's drug produces average body weight reductions of between 8.6% and 12.6% over 26 weeks, varying by dosage. Elecoglipron's 10.5% midpoint result sits within that range and its continuing trajectory at 36 weeks offers a potential point of differentiation.
The broader oral GLP-1 market is one of the most closely watched in global pharmaceuticals. Injectable therapies from Novo Nordisk and Lilly have reshaped the obesity treatment landscape, but the prospect of an effective pill has long been seen as the next frontier, given patient preference for oral administration and the logistics advantages over weekly injections. AstraZeneca's phase III advancement keeps it among the credible challengers for a share of that market.
